GIP/GLP-1 Dual Agonist

Tirzepatide:
The Fat Loss Upgrade

Semaglutide opened the door. Tirzepatide walked through it. The addition of GIP agonism to the GLP-1 pathway produced average weight loss of 20.9% in clinical trials — numbers that hadn't been seen outside of bariatric surgery.

The Clinical Trial Numbers

Trial / Dose	Average Weight Loss	Duration	Notes
SURMOUNT-1 (5mg)	15.0%	72 weeks	Mostly fat mass
SURMOUNT-1 (10mg)	19.5%	72 weeks	Mostly fat mass
SURMOUNT-1 (15mg)	20.9%	72 weeks	Mostly fat mass
vs Semaglutide 2.4mg	+3–5% more than sema	SURMOUNT-5	Superior fat selectivity

Why It Works Better Than Semaglutide

Tirzepatide hits two receptors. Semaglutide hits one. That's not a marketing claim — it's the mechanistic reason for the superior outcomes.

GLP-1 Receptor

Appetite suppression, gastric emptying reduction, insulin secretion enhancement, direct hepatic fat oxidation. This is the mechanism semaglutide also uses — tirzepatide adds the second pathway on top of it.

GIP Receptor (unique to tirzepatide)

GIP is glucose-dependent insulinotropic polypeptide. It enhances GLP-1's effects, improves adipose tissue metabolism, and — critically — does not cause nausea at the same rate as GLP-1 alone. This is why tirzepatide users report better tolerability than semaglutide despite greater fat loss.

Titration Protocol

The titration schedule exists for a reason. Your GI system needs time to adapt. Rushing it causes unnecessary side effects and dropout. Don't be impatient — the fat loss accelerates as you go up in dose.

Weeks	Dose	Frequency	Notes
1–4	2.5 mg	Once weekly	Mandatory starting dose. Don't skip this phase — GI tolerance is built here.
5–8	5 mg	Once weekly	First real fat loss acceleration. Most people feel the appetite suppression clearly here.
9–12	7.5 mg	Once weekly	Continue if tolerating 5mg well. Side effects should have stabilized.
13–16	10 mg	Once weekly	Strong therapeutic range. Many people find their optimal dose here.
17–20	12.5 mg	Once weekly	Advanced. Only if 10mg is well-tolerated and results have plateaued.
21+	15 mg	Once weekly	Maximum clinical dose. SURMOUNT trial ceiling. Diminishing returns above this.

Side Effects — What's Normal, What to Fix

Nausea

Common · First few weeks of each dose increase

Take before bed, eat small low-fat meals. Improve by week 3.

Constipation

Common · Ongoing

Increase fiber, magnesium, water. Slowed gastric transit is the mechanism.

Muscle loss concern

Preventable · In caloric deficit

CJC-1295/Ipamorelin pre-sleep, resistance training, adequate protein (1g/lb bodyweight).

Fatigue (initial)

Mild · First 1–2 weeks

Normal adaptation. Electrolytes help. Passes quickly.

Injection site reactions

Rare · Site-specific

Rotate injection sites, warm vial to room temp.

Protect Your Muscle

Tirzepatide is excellent at driving fat loss. It is not selective — in the absence of resistance training and adequate protein, it will also drive muscle loss. The clinical trial subjects who maintained the best lean mass ratios were those who lifted and ate protein.

The peptide solution: add CJC-1295/Ipamorelin pre-sleep. The GH pulse maintains muscle protein synthesis and preferentially drives fat as the fuel source. This is the difference between looking like you lost weight and looking like you transformed your body composition.

Add CJC-1295/Ipamorelin 100 mcg each, pre-sleep, throughout your tirzepatide protocol